Here is the synopsis of our sample research paper on Celera Genomics. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
This 5 page paper provides a general and financial overview of this innovative company. One of its major products are highlighted and the company's future is discussed. Bibliography lists 5 sources.
Page Count:
5 pages (~225 words per page)
File: RT13_SA326CRA.rtf
Buy This Term Paper »
 
Unformatted sample text from the term paper:
1998 Web site: http://www.celera.com Ticker symbol: CRA Exchange: NYSE Most recent closing price: 10.7 (6/24/03) High and low for last 52 weeks High 10.94 Low 10.7 Report Date: June 25,
2003 Principal business: Advanced genomic text analysis supercomputing technology. Principal market SIC Codes: 8731 - Commercial Physical & Bio Research 7379 - Computer Related Services, Not Elsewhere Classified NAICS Codes 541710
- Research and Development in the Physical Sciences and Engineering Sciences 541512 - Computer Systems Design Services Note: Source for entire chart above (Part I) is Celera
Genomics Group. Business & Company Resources Center (Gale Group). 25 June 2003. II. Financials Summary financials (in Millions): Current Assets 2002 2001 Cash & Equivalents $889 $996
Accounts Receivable $30 $24 Inventories $2 $6 Total Current Assets $938 $1,031
Total Assets $1,250 $1,220 Liabilities & Stockholders Equity Liabilities Accounts Payable $12 $21
Short-Term Debt $0 $0 Other Current Liabilities $85 $65 Total Current Liabilities $98 $86 Long-Term Debt $18 $0 Total Liabilities $149 $109 Note: Source for
chart above (Part II) is Celera. 25 Jun 2003. III. Other Data Year of IPO: 2000i Products already launched: The Celera Discovery SystemTM (CDS) online platform Earnings
per Share (2002): -$3.21ii Principal strategic partner: It is difficult to denote just one strategic partner for this innovative company as Celera is tied to a
multitude of firms. First, it should be noted that Celera Genomics Group cleared a significant hurdle when it mapped the human genome, but the company believes that studying proteins will
...